EcoDrugPlus


Keyword(s):	Human Metabolites
Molecule Category	Free-form
EPA CompTox	DTXSID70582803

Keyword(s):

Human Metabolites

Molecule Category

Free-form

EPA CompTox

DTXSID70582803


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	GDUPBUZZJUIEDX-UHFFFAOYSA-N
Smiles	CC12CCC3C(CCc4cc(OCc5ccccc5)ccc34)C1CC(O)C2O
InChI	InChI=1S/C25H30O3/c1-25-12-11-20-19-10-8-18(28-15-16-5-3-2-4-6-16)13-17(19)7-9-21(20)22(25)14-23(26)24(25)27/h2-6,8,10,13,20-24,26-27H,7,9,11-12,14-15H2,1H3

InChI Key

GDUPBUZZJUIEDX-UHFFFAOYSA-N

Smiles

CC12CCC3C(CCc4cc(OCc5ccccc5)ccc34)C1CC(O)C2O

InChI

InChI=1S/C25H30O3/c1-25-12-11-20-19-10-8-18(28-15-16-5-3-2-4-6-16)13-17(19)7-9-21(20)22(25)14-23(26)24(25)27/h2-6,8,10,13,20-24,26-27H,7,9,11-12,14-15H2,1H3

Property Name	Value
Molecular Formula	C25H30O3
Molecular Weight	378.22
AlogP	4.45
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	3.0
Polar Surface Area	49.69
Molecular species	None
Aromatic Rings	2.0
Heavy Atoms	28.0

Property Name

Value

Molecular Formula

C25H30O3

Molecular Weight

378.22

AlogP

4.45

Hydrogen Bond Acceptor

3.0

Hydrogen Bond Donor

2.0

Number of Rotational Bond

3.0

Polar Surface Area

49.69

Molecular species

None

Aromatic Rings

2.0

Heavy Atoms

28.0

Resources	Reference
CAS NUMBER	18650-87-8
NORMAN SUSDAT
PubChem	3271
ChemSpider	3156.0

Resources

Reference

CAS NUMBER

18650-87-8

NORMAN SUSDAT

PubChem

3271

ChemSpider

3156.0


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

(16ALPHA,17BETA)-3-(BENZYLOXY)ESTRA-1,3,5(10)-TRIENE-16,17-DIOL

Structure

Physicochemical Descriptors

Cross References